Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Total Non-Current Liabilities (2018)

Dianthus Therapeutics has reported Total Non-Current Liabilities over the past 1 years, most recently at $1.2 million for Q4 2018.

  • Quarterly results put Total Non-Current Liabilities at $1.2 million for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $1.2 million (changed N/A YoY), and the annual figure for FY2018 was $1.2 million, changed.
  • Total Non-Current Liabilities for Q4 2018 was $1.2 million at Dianthus Therapeutics, up from $1.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for DNTH hit a ceiling of $1.2 million in Q4 2018 and a floor of $796000.0 in Q2 2018.